Alan D Feiger

Summary

Publications

  1. ncbi Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial
    Alan D Feiger
    Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
    J Clin Psychiatry 67:1354-61. 2006
  2. ncbi A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder
    Alan D Feiger
    Depression Center, University of Colorado, Aurora, CO, USA
    CNS Spectr 14:41-50. 2009
  3. ncbi Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder
    Alan D Feiger
    Feiger Health Research Center, Wheat Ridge, CO 80033, USA
    J Clin Psychiatry 64:243-9. 2003
  4. ncbi Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies
    Alan D Feiger
    Feiger Health Research Center, Wheat Ridge, Colorado 80033, USA
    Int Clin Psychopharmacol 18:203-10. 2003
  5. ncbi Interview quality and signal detection in clinical trials
    Kenneth A Kobak
    Am J Psychiatry 162:628. 2005
  6. ncbi Rating the raters: assessing the quality of Hamilton rating scale for depression clinical interviews in two industry-sponsored clinical drug trials
    Nina Engelhardt
    MedAvante, Inc MedAvante, Ewing, NJ, USA
    J Clin Psychopharmacol 26:71-4. 2006

Detail Information

Publications6

  1. ncbi Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial
    Alan D Feiger
    Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
    J Clin Psychiatry 67:1354-61. 2006
    ..This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD)...
  2. ncbi A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder
    Alan D Feiger
    Depression Center, University of Colorado, Aurora, CO, USA
    CNS Spectr 14:41-50. 2009
    ..This research compares the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) versus placebo in treating major depressive disorder...
  3. ncbi Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder
    Alan D Feiger
    Feiger Health Research Center, Wheat Ridge, CO 80033, USA
    J Clin Psychiatry 64:243-9. 2003
    ..To assess the efficacy and tolerability of the 5-HT(1A) agonist gepirone in extended-release formulation (gepirone-ER) versus placebo in patients with major depressive disorder...
  4. ncbi Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies
    Alan D Feiger
    Feiger Health Research Center, Wheat Ridge, Colorado 80033, USA
    Int Clin Psychopharmacol 18:203-10. 2003
    ..16) in the anxious-depression subgroup. Overall, sertraline and fluoxetine showed comparable antidepressant efficacy, although sertraline may offer an advantage in those patients with severe depression...
  5. ncbi Interview quality and signal detection in clinical trials
    Kenneth A Kobak
    Am J Psychiatry 162:628. 2005
  6. ncbi Rating the raters: assessing the quality of Hamilton rating scale for depression clinical interviews in two industry-sponsored clinical drug trials
    Nina Engelhardt
    MedAvante, Inc MedAvante, Ewing, NJ, USA
    J Clin Psychopharmacol 26:71-4. 2006
    ..We evaluated the quality of Hamilton Rating Scale for Depression (HAM-D) clinical interviews performed at baseline in 2 similar multicenter, randomized, placebo-controlled depression trials sponsored by 2 pharmaceutical companies...